Metabolomics analysis of the lumbar spine after alendronate sodium intervention in ovariectomized rats with osteoporosis

doi:10.12307/2025.375

Abstract

Abstract: BACKGROUND: Studies have reported that alendronate intake significantly increases bone mineral density in patients with osteoporosis.
OBJECTIVE: To analyze and compare the changes in metabolites before and after alendronate intervention in ovariectomized rats by chromatography-mass spectrometry, and to further explore the specific mechanism and target of alendronate in the treatment of osteoporosis.
METHODS: A total of 36 female Sprague-Dawley rats were randomly divided into model group, alendronate sodium group and sham operation group. The osteoporosis model was established by ovariectomy in the first two groups. Four weeks after modeling, the rats in the alendronate group were intragastrically given alendronate sodium, while those in the sham operation group and model group were given equal volume of normal saline. After 12 weeks of continuous gavage, the metabolites of the lumbar spine were analyzed by chromatography-mass spectrometry, and the common differential metabolites were obtained, which were analyzed by bioinformatics such as Kyoto Gene and Genome Encyclopedia pathway.
RESULTS AND CONCLUSION: Totally 17 different metabolites were obtained in the three groups. The enrichment analysis of the Kyoto Encyclopedia of Genes and Genomes showed that alendronate sodium could regulate unsaturated fatty acid biosynthesis, linoleic acid metabolism and other pathways to protect ovariectomized rats. These results indicate that alendronate sodium may exert its anti-osteoporosis effect by interfering with unsaturated fatty acid bioanabolism and linoleic acid metabolism, so as to achieve the purpose of preventing osteoporosis.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: osteoporosis, metabolomics, alendronate sodium, linoleic acid metabolism, unsaturated fatty acid biosynthesis, differential metabolite, chromatography-mass spectrometry, traditional Chinese medicine

CLC Number:

Chen Xinfei, Dai Yahui, Xie Bingying, Huang Xiaobin, Huang Huimin, Huang Jingwen, Li Shengqiang, Ge Jirong. Metabolomics analysis of the lumbar spine after alendronate sodium intervention in ovariectomized rats with osteoporosis[J]. Chinese Journal of Tissue Engineering Research, 2025, 29(11): 2277-2284.

Figures/Tables 9

References

[1] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2022)[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(6):573-611.
[2] HARRIS K, ZAGAR CA, LAWRENCE KV. Osteoporosis: Common Questions and Answers. Am Fam Physician. 2023;107(3):238-246.
[3] No authors listed. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973-997.
[4] ARCEO-MENDOZA RM, CAMACHO PM. Postmenopausal Osteoporosis: Latest Guidelines. Endocrinol Metab Clin North Am. 2021;50(2):167-178.
[5] AYERS C, KANSAGARA D, LAZUR B, et al. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2023; 176(2):182-195.

[6] NGUYEN PV, BOUIN M, STE-MARIE LG. Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients. Osteoporos Int. 2021; 32(1):193-197.

[7] NICHOLSON JK, LINDON JC, HOLMES E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29(11):1181-1189.
[8] 魏丽英,李景欣. HPLC法对阿仑膦酸钠成分的测定[J].北方药学, 2021,18(12):1-3.
[9] WANG Q, YU Q, ZENG P, et al. Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis. J Clin Pharmacol. 2023; 63(4):455-465.
[10] GEHRKE B, ALVES COELHO MC, BRASIL D’ALVA C, et al. Long-term consequences of osteoporosis therapy with bisphosphonates. Arch Endocrinol Metab. 2023;68:e220334.
[11] 陈赛楠,吴华嵩,程佑民,等.续苓健骨方对去卵巢骨质疏松模型大鼠血液钙磷代谢的影响 [J].中国骨质疏松杂志,2019,25(4): 528-532.
[12] 张海永,黄景文,谢冰颖,等.骨疏康治疗去卵巢大鼠骨质疏松的腰椎代谢组学分析[J].中国组织工程研究,2022,26(32):5185-5190.
[13] Cummings SR, Santora AC, Black DM, et al. History of alendronate. Bone. 2020;137:115411.
[14] Wilkins Parker LR, Preuss CV. Alendronate. 2023 // StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
[15] CHANDRAN M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab. 2022;66(5):724-738.
[16] SHEN J, KE Z, DONG S, et al. Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis. Med Sci Monit. 2022;28:e935491.
[17] PIRIYAKHUNTORN P, TANTIWORAWIT A, PHIMPHILAI M, et al. The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial.Front Endocrinol (Lausanne). 2023;14:1178761.
[18] 朱忠华,唐丽琴,张世能.阿仑膦酸钠联合辛伐他汀通过Wnt/β-catenin信号通路对去卵巢骨质疏松大鼠的影响[J].中国骨质疏松杂志,2021,27(5):704-708.
[19] 马广丽,臧巧源,杨青,等.阿仑膦酸钠治疗骨质疏松对骨密度与血清Klotho蛋白水平的影响[J].中国医药,2023,18(5):709-713.
[20] TSUJI A, IKEDA Y, YOSHIKAWA S, et al. The Tryptophan and Kynurenine Pathway Involved in the Development of Immune-Related Diseases.Int J Mol Sci. 2023;24(6):5742.
[21] BALLESTEROS J, RIVAS D, DUQUE G. The Role of the Kynurenine Pathway in the Pathophysiology of Frailty, Sarcopenia, and Osteoporosis. Nutrients. 2023;15(14):3132.
[22] HUANG M, XU S, LIU L, et al. m6A Methylation Regulates Osteoblastic Differentiation and Bone Remodeling. Front Cell Dev Biol. 2021;9: 783322.
[23] HAN J, KONG H, WANG X, et al. Novel insights into the interaction between N6-methyladenosine methylation and noncoding RNAs in musculoskeletal disorders. Cell Prolif. 2022;55(10):e13294.
[24] CHEN J, TIAN Y, ZHANG Q, et al. Novel Insights Into the Role of N6-Methyladenosine RNA Modification in Bone Pathophysiology. Stem Cells Dev. 2021;30(1):17-28.
[25] WU Y, XIE L, WANG M, et al. “Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. Nat Commun. 2018;9(1):4772.
[26] TIAN C, HUANG Y, LI Q, et al. Mettl3 Regulates Osteogenic Differentiation and Alternative Splicing of Vegfa in Bone Marrow Mesenchymal Stem Cells. Int J Mol Sci. 2019;20(3):551.
[27] LIN G, WANG H, DAI J, et al. Conjugated linoleic acid prevents age-induced bone loss in mice by regulating both osteoblastogenesis and adipogenesis. Biochem Biophys Res Commun. 2017;490(3):813-820.
[28] RAHMAN MM, FERNANDES G, WILLIAMS P. Conjugated linoleic Acid prevents ovariectomy-induced bone loss in mice by modulating both osteoclastogenesis and osteoblastogenesis. Lipids. 2014;49(3):211-224.
[29] FENG W, WANG X, HUANG D, et al. Role of diet in osteoporosis incidence: Umbrella review of meta-analyses of prospective observational studies. Crit Rev Food Sci Nutr. 2023;63(19):3420-3429.
[30] JIANG H, WANG L, WANG D, et al. Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality. Clin Nutr. 2022;41(8):1798-1807.
[31] ENGELEN M, JONKER R, SULAIMAN H, et al. ω-3 polyunsaturated fatty acid supplementation improves postabsorptive and prandial protein metabolism in patients with chronic obstructive pulmonary disease: a randomized clinical trial. Am J Clin Nutr. 2022;116(3):686-698.
[32] GHAMARZAD SHISHAVAN N, MASOUDI S, MOHAMADKHANI A, et al. The association of dietary intake and plasma fatty acid panel in pancreatic cancer patients: results from golestan cohort study.Nutr Health. 2024;30(2):319-330.
[33] TAO SS, WANG P, WANG XY, et al. Causal effect of polyunsaturated fatty acids on bone mineral density and fracture. Front Nutr. 2022; 9:1014847.
[34] GAO J, XIE C, YANG J, et al. The Effects of n-3 PUFA Supplementation on Bone Metabolism Markers and Body Bone Mineral Density in Adults: A Systematic Review and Meta-Analysis of RCTs. Nutrients. 2023;15(12):2806.
[35] DOU Y, WANG Y, CHEN Z, et al. Effect of n-3 polyunsaturated fatty acid on bone health: A systematic review and meta-analysis of randomized controlled trials. Food Sci Nutr. 2021;10(1):145-154.
[36] MARTÍNEZ-RAMÍREZ MJ, PALMA S, MARTÍNEZ-GONZÁLEZ MA, et al. Dietary fat intake and the risk of osteoporotic fractures in the elderly. Eur J Clin Nutr. 2007;61(9):1114-1120.
[37] COETZEE M, HAAG M, KRUGER MC. Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells. J Nutr Biochem. 2007;18(1):54-63.
[38] JÄRVINEN R, TUPPURAINEN M, ERKKILÄ AT, et al. Associations of dietary polyunsaturated fatty acids with bone mineral density in elderly women. Eur J Clin Nutr. 2012;66(4):496-503.
[39] PHOEMSAPTHAWEE J, RUANGTHAI R, TUMNAK P, et al. Synergistic Effects of Combined Concurrent Training and Eri-Polyunsaturated Fatty Acid Supplementation on Bone Mineral Density, Muscle Strength, and Inflammation. Prev Nutr Food Sci. 2023;28(1):10-20.
[40] LAU BY, COHEN DJ, WARD WE, et al. Investigating the role of polyunsaturated fatty acids in bone development using animal models. Molecules. Molecules. 2013;18(11):14203-14227.
[41] BENOVA A, FERENCAKOVA M, BARDOVA K, et al. Omega-3 PUFAs prevent bone impairment and bone marrow adiposity in mouse model of obesity. Commun Biol. 2023;6(1):1043.
[42] ORCHARD TS, CAULEY JA, FRANK GC, et al. Fatty acid consumption and risk of fracture in the Women’s Health Initiative. Am J Clin Nutr. 2010;92(6):1452-1460.